Literature DB >> 21796761

Frequency, risk-factors and survival of children with atypical teratoid rhabdoid tumors (AT/RT) of the CNS diagnosed between 1988 and 2004, and registered to the German HIT database.

Katja von Hoff1, Bernward Hinkes, Elke Dannenmann-Stern, André O von Bueren, Monika Warmuth-Metz, Niels Soerensen, Angela Emser, Isabella Zwiener, Paul G Schlegel, Joachim Kuehl, Michael C Frühwald, Rolf D Kortmann, Torsten Pietsch, Stefan Rutkowski.   

Abstract

PURPOSE: To analyze the frequency, prognostic factors, and outcome of children with atypical teratoid/rhabdoid tumors (AT/RT), a rare and highly malignant embryonal brain tumor.
MATERIALS AND METHODS: Clinical data of patients diagnosed between 1988 and 2004 with AT/RT who were registered to the German HIT trial center, were correlated with outcome. Patient numbers for AT/RT were compared to numbers for primitive neuroectodermal tumors and medulloblastomas (PNET/MB) registered to the population-based HIT trials.
RESULTS: We identified 56 patients with the centrally confirmed histopathological diagnosis of AT/RT with a median age of 1.2 years (range, 0.1-14.0 years). The AT/RT:PNET/MB ratio was 1:12.2 for all children, and 1:1.5 for children younger than 1 year at diagnosis. Three-year overall survival (OS) and event-free survival (EFS) for all patients were 22% and 13%, respectively. Eight patients (14%) are considered long-term event-free survivors (follow-up 1.4-10.6 years). By univariable analyses, younger age, metastatic disease, infratentorial location, and less than complete remission at the end of chemotherapy were identified as negative influencing factors for OS. By multivariable analyses, younger age (OS, EFS) and metastatic disease (OS) were identified as independent risk factors.
CONCLUSION: The incidence of AT/RT in children below 1 year is higher than previously reported. A subset of patients with favorable clinical risk factors profits from intensive multimodal treatment. Prospective clinical and biological studies are needed to further define prognostic factors and optimize therapy.
Copyright © 2011 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2011        PMID: 21796761     DOI: 10.1002/pbc.23236

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  44 in total

1.  Tumor control and QoL outcomes of very young children with atypical teratoid/rhabdoid tumor treated with focal only chemo-radiation therapy using pencil beam scanning proton therapy.

Authors:  Damien C Weber; Carmen Ares; Robert Malyapa; Francesca Albertini; Gabriele Calaminus; Ulrike Kliebsch; Lorentzos Mikroutsikos; Petra Morach; Alessandra Bolsi; Tony Lomax; Ralf Schneider
Journal:  J Neurooncol       Date:  2014-11-02       Impact factor: 4.130

2.  Atypical teratoid rhabdoid tumor: long-term survival after chemoradiotherapy.

Authors:  Vivek Verma; Catrina P Johnson; Nathan R Bennion; Abhijeet R Bhirud; Sicong Li; Rodney D McComb; Chi Lin
Journal:  Childs Nerv Syst       Date:  2015-05-05       Impact factor: 1.475

3.  Overall Survival of Primary Intracranial Atypical Teratoid Rhabdoid Tumor Following Multimodal Treatment: A Pooled Analysis of Individual Patient Data.

Authors:  Xiu-Jian Ma; Da Li; Liang Wang; Shu-Yu Hao; Li-Wei Zhang; Jun-Ting Zhang; Zhen Wu
Journal:  Neurosurg Rev       Date:  2018-12-08       Impact factor: 3.042

4.  Cutaneous malignant rhabdoid tumor in the palm of an adult.

Authors:  Masaki Fujioka; Kenji Hayashida; Chikako Murakami; Masanori Hisaoka; Yoshinao Oda; Masahiro Ito
Journal:  Rare Tumors       Date:  2013-07-12

5.  Long-term survival following additive radiotherapy in patients with atypical teratoid rhabdoid tumors.

Authors:  Khaled Elsayad; Jan Kriz; Laith Samhouri; Uwe Haverkamp; Ronald Straeter; Walter Stummer; Hans Theodor Eich
Journal:  Strahlenther Onkol       Date:  2016-06-07       Impact factor: 3.621

6.  Embryonal tumors in Canadian children less than 36 months of age: results from the Canadian Pediatric Brain Tumor Consortium (CPBTC).

Authors:  E Story; D L Johnston; U Bartels; A S Carret; B Crooks; D D Eisenstat; C Fryer; L Lafay-Cousin; V Larouche; B Wilson; S Zelcer; M Silva; J Brossard; E Bouffet; D L Keene
Journal:  J Neurooncol       Date:  2017-05-16       Impact factor: 4.130

Review 7.  Atypical teratoid/rhabdoid tumors-current concepts, advances in biology, and potential future therapies.

Authors:  Michael C Frühwald; Jaclyn A Biegel; Franck Bourdeaut; Charles W M Roberts; Susan N Chi
Journal:  Neuro Oncol       Date:  2016-01-10       Impact factor: 12.300

8.  The descriptive epidemiology of atypical teratoid/rhabdoid tumors in the United States, 2001-2010.

Authors:  Quinn T Ostrom; Yanwen Chen; Peter M de Blank; Annie Ondracek; Paul Farah; Haley Gittleman; Yingli Wolinsky; Carol Kruchko; Mark L Cohen; Daniel J Brat; Jill S Barnholtz-Sloan
Journal:  Neuro Oncol       Date:  2014-05-20       Impact factor: 12.300

Review 9.  Primary atypical teratoid/rhabdoid tumor of central nervous system in children: a clinicopathological analysis and review of literature in China.

Authors:  Min Yang; Xi Chen; Ning Wang; Kun Zhu; Ying-Zi Hu; Yun Zhao; Yan Shu; Man-Li Zhao; Wei-Zhong Gu; Hong-Feng Tang
Journal:  Int J Clin Exp Pathol       Date:  2014-04-15

10.  Long-term survival of an infant with an atypical teratoid/rhabdoid tumor following subtotal resection and low-cumulative dose chemotherapy: a case report.

Authors:  Viktor Arnhold; Florian Oyen; Reinhard Schneppenheim; Hannes Haberl; Arend Koch; Michael C Frühwald; Pablo Hernáiz Driever
Journal:  Childs Nerv Syst       Date:  2016-01-08       Impact factor: 1.475

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.